New drug shows potential to improve survival for pancreatic cancer patients
Research suggests that a new medication may significantly enhance survival rates for individuals with advanced pancreatic cancer. The drug targets a specific mutated protein linked to tumor growth. (sources: cbsnews, fortune, reuters)
The medication, daraxonrasib, has demonstrated potential in extending survival for patients with advanced pancreatic cancer. It inhibits a mutated protein that is involved in tumor growth in a majority of cases.
- Daraxonrasib targets a specific mutated protein, which is present in over 90% of pancreatic cancer cases.
- Patients using daraxonrasib have reported improved quality of life alongside increased survival rates.
- The research indicates a significant advancement in treatment options for pancreatic cancer, a disease characterized by low survival rates.
Why it matters
This development represents a potential breakthrough in the treatment of a challenging cancer type, offering hope for improved outcomes.
↓ Congress can act on this
3 bills on this issue are moving right now — and the most active one is HR4101: Cancer Drug Parity Act of 2025.
HR4101 · 119th Congress
Cancer Drug Parity Act of 2025
Where do you stand on this bill?
Takes about 60 seconds
About this bill
What HR4101 actually does
This story is about Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. This bill would pancreatic: Require group health plans to apply cost-sharing for oral anticancer drugs no less favorably than provider-administered anticanc.
If passed, it would:
- Require group health plans to apply cost-sharing for oral anticancer drugs no less favorably than • Potentially reduce out-of-pocket costs for patients prescribed oral cancer therapies.
2 other bills moving on this issue
Take action on any of them individually.
This story is about New drug significantly improves survival for pancreatic cancer patients. This bill would Expand coverage of certain cancer diagnostic/laboratory tests (including next-generation sequencing) in Medicare/Medicaid/CHIP.
If passed, it would
- Expand coverage of certain cancer diagnostic/laboratory tests (including next-generation sequencing) in • Create an HHS education/awareness program on genomic testing and genetic counselors.
This story is about Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. This bill would support broader, more representative enrollment to speed evidence generation for serious diseases.
If passed, it would
- Enable/clarify pathways for sponsors to support trial participation costs (e.g., travel, technology • Support broader, more representative enrollment to speed evidence generation for serious diseases (including cancers.
Top coverage · 4 sources